Nationally-known oncologists and researchers at The Center for Cancer & Blood Disorders at Connecticut Children’s are developing personalized treatment plans based on whole genome analysis of tumors. Its partnership with The Jackson Laboratory in the area of genomic research has led to the development of a new brain tumor clinical trial using the medication Digoxin for recurrent medulloblastoma, as part of expanded trials for its neuro-oncology program. This clinical trial opened in September 2024 at 34 hospitals across the U.S. As a member of Children’s Oncology Group, the Beat Childhood Cancer Research Consortium and the National Pediatric Cancer Foundation’s Sunshine Project, the center has more than 65 active clinical trials open at any time. The center’s comprehensive fertility and sexual health program was recently awarded a $1.36 million National Cancer Institute and National Institutes of Health grant for research on sexual and reproductive health of adolescent and young adults undergoing cancer treatment.
